Romera Irene, Cebrián-Cuenca Ana, Álvarez-Guisasola Fernando, Gomez-Peralta Fernando, Reviriego Jesús
Eli Lilly and Company, Madrid, Spain.
Centro de Salud San Antón, Cartagena, Spain.
Diabetes Ther. 2019 Feb;10(1):5-19. doi: 10.1007/s13300-018-0535-9. Epub 2018 Nov 30.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well established as effective treatments for patients with type 2 diabetes. GLP-1 RAs augment insulin secretion and suppress glucagon release via the stimulation of GLP-1 receptors. Although all GLP-1 RAs share the same underlying mechanism of action, they differ in terms of formulations, administration, injection devices and dosages. With six GLP-1 RAs currently available in Europe (namely, immediate-release exenatide, lixisenatide, liraglutide; prolonged-release exenatide, dulaglutide and semaglutide), each with its own characteristics and administration requirements, physicians caring for patients in their routine practice face the challenge of being cognizant of all this information so they are able to select the agent that is most suitable for their patient and use it in an efficient and optimal way. The objective of this review is to bring together practical information on the use of these GLP-1 RAs that reflects their approved use.Funding: Eli Lilly and Company.Plain Language Summary: Plain language summary available for this article.
胰高血糖素样肽-1受体激动剂（GLP-1 RAs）已被确认为治疗2型糖尿病患者的有效药物。GLP-1 RAs通过刺激GLP-1受体增加胰岛素分泌并抑制胰高血糖素释放。尽管所有GLP-1 RAs具有相同的潜在作用机制，但它们在剂型、给药方式、注射装置和剂量方面存在差异。目前欧洲有六种GLP-1 RAs（即速释艾塞那肽、利司那肽、利拉鲁肽；缓释艾塞那肽、度拉糖肽和司美格鲁肽），每种都有其自身特点和给药要求，在日常临床工作中照顾患者的医生面临着了解所有这些信息的挑战，以便他们能够选择最适合其患者的药物并以高效和最佳方式使用。本综述的目的是汇集有关这些GLP-1 RAs使用的实用信息，这些信息反映了它们的获批用途。资助：礼来公司。简明语言摘要：本文提供简明语言摘要。
